Slide 1: Consolidated Financial Results for Q3 2025 and Development Outlook
Consolidated Financial Results for Q3 2025 and Development Outlook
Slide 2: Disclaimer
Disclaimer This presentation has been prepared for informational purposes only and does not constitute an offer or invitation to purchase or subscribe for any securities of Celon Pharma S.A. (the “Company”). It does not constitute investment advice, financial advice, legal advice, tax advice, or any
Slide 3: Financial Results - Segment Analysis
Financial Results - Segment Analysis Results show a clear change in the revenue structure – the growing importance of the generics segment offsets the temporary decline in the innovative segment. Segment Q32025 (PLN m) Q32024 (PLN m) YoY Change Generics (Poland) 117 359 104 861 +12% Generics (Export
Slide 4: Detailed Group Financial Results (All segments)
Detailed Group Financial Results (All segments) Q1'25 Q2'25 Q3'25 9M-2025 9M-2024* 9M'25 / 9M'24* Revenues 49 334 56 601 74 057 179 992 158 805 13% Revenues from sales of medicines 48 572 51 076 51 708 151 356 139 126 9% Other revenues 747 783 2 926 4 456 3 320 34% Revenues from grants 15 4 742 19 4
Slide 5: Strong Revenue Growth Increased EBITDA Margin
Strong Revenue Growth Increased EBITDA Margin 13.3% overall, driven by: 4.5% (+2.5 p.p.), resulting from: • Increasing sales of medicines (+8.8%) • Favorable revenue mix • Significant rise in grants (+47.8%) • Cost discipline • Higher other revenues • Growing share of the generics segment in the Gro
Slide 6: Analysis of the Generics segment (in thousands PLN)
Analysis of the Generics segment (in thousands PLN) All amounts in Q1'25 Q2'25 Q3'25 9M-2025 9M-2024* 9M'25 / 9M'24 thousand PLN Revenues 48 978 51 179 52 415 152 572 141 896 8% Revenues from 48 572 51 076 51 708 151 356 139 126 9% sales of medicines Other revenues 406 103 707 1 216 2 770 -56% Reven
Slide 7: Revenue Increase Domestic Sales Momentum Export Decline
Revenue Increase Domestic Sales Momentum Export Decline 7.5% overall revenue increase, primarily driven Domestic sales maintained very strong Exports declined by 4.9% due to delivery shifts by strong medicine sales (+8.8%). momentum with a +11.9% growth. in the period. EBITDA Margin Segment Stabilit
Slide 8: Generics - Domestic Market Performance
Generics - Domestic Market Performance Strong performance in the domestic generics market, driven by portfolio growth and strategic initiatives. PLN 114.7M Product Performance (9M 2024 vs 9M 2025) Total Revenues (9M 2025) +12% Year-over-Year Growth Key Performance Drivers • Growth across most portfo
Slide 9: Analysis of the R&D Segment Results for Q3 2025
Analysis of the R&D Segment Results for Q32025 Q1'25 Q2'25 Q3'25 9M-2025 9M-2024* 9M'25 / 9M'24 Revenues 356 5 422 21 642 27 420 16 909 62% Other revenues 341 680 2 219 3 240 550 489% Revenues from grants 15 4 742 19 423 24 180 16 359 48% Domestic 15 4 741 19 424 24 180 16 359 48% Export 341 680 2 2
Slide 10: Innovation Segment Performance Highlights
Innovation Segment Performance Highlights 62% Revenue Growth Driven mainly by a higher level of grants (+47.8%) and an increase in other revenues. 10% Rise in Operating Expenses Reflecting the intensification of R&D activities and preparations for subsequent stages of clinical development. EBITDA Ma
Slide 11: Active Clinical Pipeline - Status
Active Clinical Pipeline - Status Falkieri/Novohale (Neuropsychiatry): CPL’36 (Schizophrenia, Parkinson’s CPL’116 (Inflammatory diseases, dyskinesias): Myasthenia Gravis): NMDAR agonist/Esketamine, Phase 2 PDE10A inhibitor, Phases 1 & 2 completed, JAK/ROCK inhibitor, Phases 1 & 2 completed, complete
Slide 12: New Funding Sources
New Funding Sources National Recovery Plan Programme (KPO): TRANSMED I (ABM) 3 4 Signed agreements Grants filed 31,5+ 39 mln zł mln zł Funds allocated to the development of innovative projects The projects focus on the field of translational medicine, and the expansion of the generics portfolio, whi
Slide 13: Financing Strategy for R&D Segment Development
Financing Strategy for R&D Segment Development Diversification of sources Grant opportunities Active search for various forms of financing for R&D projects Systematic participation in national and European competitions Reducing dependence on individual grant programs Leveraging the team’s experience
Slide 14: New production Facility in Slovakia
New production Facility in Slovakia Location Purpose Žilina region, Slovakia Manufacturing type II diabetes medicines and metabolic medicines Active Substance Trade Name GLP-1 - analogs Reduzek Key Activities Financing Adaptation, equipping, and commencement Credit facility (EBRD up to EUR 23 mln) o